Good evening Dave and Joe,
Joe, I'll have to go with Dave on this one. <g> LOL
Thanks for the clarification. I am in agreement to get it right.
Perhaps the best wording would be
1. "DMX 'formally' announced July 18 to acquire OXO 'as soon as ... the last patient was enrolled and the Phase III closed."
2. <<nothing speaks louder about the phase III results
than the fact that DMX announced their intention to buy Oxo as soon as the [blind was lifted] last patient was enrolled and Phase III closed, then announced several
months later (after doing their DD) that they were going ahead with the deal.>>
So when exactly does the Phase III become unblinded? When the database is locked or when it becomes known which patients are in the placebo group or the WF10 group? When its published?
----------------------------
Clippings I gathered from my searches and post from SI may have contributed to my understanding of unblinding:
And I posted twice, once in May then in July:
"di7026 (ID#: 38005) WF10 AIDS TRIAL 5/24/01 07:52 3646664
As confirmed by Dr. Pugen, the Phase III trial will break in the third week of June. We
should expect info concerning the data some time after that."
di7026 (ID#: 38005) RE: UPDATE 7/9/01 15:13 3861861
"When will they unblind the phase III trial?" As I had posted before, Dr.Pugen of the
www.wf10.com has informed me that the WF10 phase III trial was unblinded at the
end of June, 2001. But gathering and analysis of data will take some time."
bluejay (ID#: 36864)
WF10 results Expected Date - Repost
7/28/01 10:29
3944240
« Previous Message
Next Message »
Just to clarify the expectations, below is a repost of an e-mail response I received
from Oxo on May 30 (bolding is mine):
we are expecting the last patients to complete their review period by
the end of June, early July. Once the last patient has officially
finished the study, the complete collected data will be analyzed and a
report prepared. This usually takes from two to four months, after which
the results will be made public.
I thank you for you interest in OXO Chemie and especially this important
HIV trial.
With kind regards,
Daniel Kuehne
Project Manager |
